FEATURE ARTICLES
Manufacturing execution system (MES) technical maturity is rising, but adoption across manufacturing sites is uneven. Organizational readiness may hold the key.
- Why Are Life Science Companies So Poorly Prepared For RIM's Future?
- [Video] Get It Right with The Gemba
- April 2026 — CDMO Opportunities And Threats Report
- GLP-1 Receptor Agonists: Metabolism, Reward Biology, And AI-Driven Drug Discovery
- Why Your MES RFP Is Failing Before It Starts
- Here's How FDA's Accelerated Approval Pathway Has Evolved Since '24
- Gaining An Edge In GLP-1 Production
PHARMA ONLINE WHITE PAPERS
-
![GettyImages-1210902094 analysis]( "Opportunities In Preclinical Development")
Opportunities In Preclinical DevelopmentEvery domain produces critical data and this data and contexual information should be captured and managed in the most effective and robust manner.
-
Selecting A CDMO For Custom Activated PEGs1/27/2026
Custom-activated PEGs require thoughtful planning and precise analytical control. Discover key considerations for selecting a partner capable of supporting scalable, compliant PEGylation.
-
Best Practices In Formulation And Lyophilization Development: Proteins, mAbs And ADCs10/16/2024
Discover how advancements in pharmaceutical freeze-drying are reshaping the process through better product understanding, precise process control, and innovations in equipment efficiency.
-
FDA's Regenerative Medicine Advanced Therapy (RMAT) Program12/10/2025
RMAT qualification requires preliminary clinical evidence demonstrating the potential to address an unmet medical need. This designation grants benefits like intensive guidance and faster FDA review.
-
Support Of Scale-Up And Technical Transfer Through Understanding Equipment10/16/2024
See how our expertise in formulation and process development can ensure a seamless scale-up from laboratory to full-scale production of lyophilized injectable products.
-
Unlocking The Potential Of Biocatalysis1/22/2026
Biocatalysis delivers cleaner, more selective pharma processes while cutting energy use and waste. Engineered enzymes broaden their reach, enabling faster development and greater sustainability.
PHARMA ONLINE APP NOTES & CASE STUDIES
NEWSLETTER ARCHIVE
- 05.14.26 -- STREAM Edition: Misconceptions And Metrics Of A Proactive CCS Strategy
- 05.13.26 -- Analytics, Aseptic Assurance, And Cleanroom Control — All In One Issue
- 05.13.26 -- How MTP Is Transforming Pharma Production Lines
- 05.12.26 -- Advancing Drug Products With The Right CDMO Partner
- 05.12.26 -- West Vantage: End-to-End Combination Product Solutions
INDUSTRY NEWS
-
![rating service, satisfaction-GettyImages-2221603596]( "ISPE Announces 2026 FOYA Winners")
ISPE Announces 2026 FOYA WinnersThese awards recognize pharmaceutical and biopharmaceutical manufacturing projects that demonstrate excellence across innovation, operations, supply chain, Pharma 4.0, and social impact.
-
![FDA Logo on phone screen-GettyImages-2208861549]( "Høeg In, Pazdur Out At The FDA")
Høeg In, Pazdur Out At The FDAWhat an eventful week it has been at the FDA, with Richard Pazdur, M.D., resigning after weeks in his position as director of Center for Drug Research and Evaluation (CDER), and his vacancy being quickly filled by acting director Tracy Beth Høeg, M.D.
-
![business peope negotiating-GettyImages-637902194]( "9 Drugs Granted Fast Track By FDA's Voucher Program")
9 Drugs Granted Fast Track By FDA's Voucher ProgramWith targets like pancreatic cancer, deafness, blindness, infertility and vaping addiction, these drugs were chosen due to an unmet need, addressing a public health crisis, boosting domestic manufacturing or increasing affordability.
-
![Pharmaceutical sorting machine, pills-GettyImages-1499814881]( "Leaders In The Excipient Market: Region And Type")
Leaders In The Excipient Market: Region And TypeThough North America led the market with a 38.32% market share of $3.15 billion in 2024, Asia Pacific is expected to have the fastest growth in the upcoming years.
-
![GettyImages-2189405678-GLP-1-obesity]( "Pfizer Strengthens Obesity Foothold With Metsera Acquisition")
Pfizer Strengthens Obesity Foothold With Metsera AcquisitionAfter discouraging efforts to bring two oral obesity drugs to market—danuglipron and lotiglipron—this acquisition launches Pfizer back into the obesity therapeutic game.
PHARMACEUTICAL ONLINE CONTENT COLLECTIONS
Explore how sterility assurance, including sterilization validation and environmental monitoring, is essential for controlling microbial contamination in mammalian cell production to ensure patient safety. Check out the latest e-book from Pharmaceutical Online.
More Content CollectionsSUPPLIER NEWS
-
Inside Information: Nanoform Signs First Exclusivity Agreement For Ultra-High Concentration Subcutaneous Delivery5/12/2026
Helsinki, Finland – Nanoform Finland Plc (“Nanoform”), the medicine performance‑enhancing company, today announced that it has signed an exclusivity agreement with a U.S. biopharmaceutical company (Nasdaq listed, Mcap USD 1Bn+) for the application of Nanoform’s proprietary biologics nanoparticle technology to support the development of differentiated subcutaneous biologic medicines.
-
Compact & Powerful Double Planetary Mixer For Lab And Pilot-Scaling4/30/2026
ROSS has delivered an ergonomic and powerful Double Planetary Mixer Model DPM-10 engineered for high-viscosity and specialty material processing in laboratory and pilot-scale operations.
-
AES Cleanroom Technology appoints John Groth As Chief Revenue Officer4/27/2026
AES Cleanroom Technology, a leading provider of modular cleanroom design, manufacturing, and construction solutions for the life sciences and biopharmaceutical industries, has appointed John Groth as Chief Revenue Officer as demand grows for flexible, high-performance manufacturing environments across pharma and biotech.
